Alamar Biosciences Valued at 1.5 Billion in Nasdaq Debut
Shares of Alamar Biosciences rose 33% today as the protein biomarker firm debuted on the Nasdaq. The company raised $191.3 million to fund disease research.
Xurve View
Xurve View
Alamar Biosciences saw its market valuation reach $1.53 billion on Friday as its shares surged 33% during their Nasdaq debut. The company's stock opened at $22.60 per share, a significant climb from the initial offering price of $17.
